We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Yourgene Health Plc | LSE:YGEN | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.515 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMYGEN
RNS Number : 5702D
Yourgene Health PLC
27 June 2019
Yourgene Health plc
("Yourgene Health")
Notice of Results
Manchester, UK - 27 June 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, will announce results for the year ended 31 March 2019 on Wednesday 10 July 2019.
For more information, please contact: Yourgene Health plc Tel: +44 (0)161 Lyn Rees, Chief Executive Officer 667 1053 Barry Hextall, Chief Financial Officer Joanne Cross, Director of Marketing investors@yourgene-health.com Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)20 7213 Liam Murray / James Caithie / Ludovico Lazzaretti 0880 Stifel Nicolaus Europe Limited (Corporate Broker) Tel: +44 (0)20 7710 Nicholas Moore / Matthew Blawat / Ben Maddison 7600 Vigo Communications (PR) Tel: +44 (0)20 7390 Ben Simons / Fiona Henson / Antonia Pollock 0238 yourgene@vigocomms.com
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORBCGDLIXDBGCL
(END) Dow Jones Newswires
June 27, 2019 02:01 ET (06:01 GMT)
1 Year Yourgene Health Chart |
1 Month Yourgene Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
